173 related articles for article (PubMed ID: 32807787)
1. Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints.
Kong YW; Dreaden EC; Morandell S; Zhou W; Dhara SS; Sriram G; Lam FC; Patterson JC; Quadir M; Dinh A; Shopsowitz KE; Varmeh S; Yilmaz ÖH; Lippard SJ; Reinhardt HC; Hemann MT; Hammond PT; Yaffe MB
Nat Commun; 2020 Aug; 11(1):4124. PubMed ID: 32807787
[TBL] [Abstract][Full Text] [Related]
2. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo.
Morandell S; Reinhardt HC; Cannell IG; Kim JS; Ruf DM; Mitra T; Couvillon AD; Jacks T; Yaffe MB
Cell Rep; 2013 Nov; 5(4):868-77. PubMed ID: 24239348
[TBL] [Abstract][Full Text] [Related]
3. A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
Song J; Yu J; Jeong LS; Lee SK
Cancer Lett; 2021 Jan; 497():54-65. PubMed ID: 33075425
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of nucleotide excision repair factor xeroderma pigmentosum group A by ataxia telangiectasia mutated and Rad3-related-dependent checkpoint pathway promotes cell survival in response to UV irradiation.
Wu X; Shell SM; Yang Z; Zou Y
Cancer Res; 2006 Mar; 66(6):2997-3005. PubMed ID: 16540648
[TBL] [Abstract][Full Text] [Related]
5. CHK1 regulates NF-κB signaling upon DNA damage in p53- deficient cells and associated tumor-derived microvesicles.
Carroll BL; Pulkoski-Gross MJ; Hannun YA; Obeid LM
Oncotarget; 2016 Apr; 7(14):18159-70. PubMed ID: 26921248
[TBL] [Abstract][Full Text] [Related]
6. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.
Cannell IG; Merrick KA; Morandell S; Zhu CQ; Braun CJ; Grant RA; Cameron ER; Tsao MS; Hemann MT; Yaffe MB
Cancer Cell; 2015 Nov; 28(5):623-637. PubMed ID: 26602816
[TBL] [Abstract][Full Text] [Related]
7. Cell Fate Regulation upon DNA Damage: p53 Serine 46 Kinases Pave the Cell Death Road.
Liebl MC; Hofmann TG
Bioessays; 2019 Dec; 41(12):e1900127. PubMed ID: 31621101
[TBL] [Abstract][Full Text] [Related]
8. The p53 binding protein PDCD5 is not rate-limiting in DNA damage induced cell death.
Bock FJ; Tanzer MC; Haschka MD; Krumschnabel G; Sohm B; Goetsch K; Kofler R; Villunger A
Sci Rep; 2015 Jun; 5():11268. PubMed ID: 26062895
[TBL] [Abstract][Full Text] [Related]
9. An Integrated Approach for Analysis of the DNA Damage Response in Mammalian Cells: NUCLEOTIDE EXCISION REPAIR, DNA DAMAGE CHECKPOINT, AND APOPTOSIS.
Choi JH; Kim SY; Kim SK; Kemp MG; Sancar A
J Biol Chem; 2015 Nov; 290(48):28812-21. PubMed ID: 26438822
[TBL] [Abstract][Full Text] [Related]
10. Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy.
Morandell S; Yaffe MB
Prog Mol Biol Transl Sci; 2012; 110():289-314. PubMed ID: 22749150
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
12. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
[TBL] [Abstract][Full Text] [Related]
13. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
14. Che-1 modulates the decision between cell cycle arrest and apoptosis by its binding to p53.
Desantis A; Bruno T; Catena V; De Nicola F; Goeman F; Iezzi S; Sorino C; Gentileschi MP; Germoni S; Monteleone V; Pellegrino M; Kann M; De Meo PD; Pallocca M; Höpker K; Moretti F; Mattei E; Reinhardt HC; Floridi A; Passananti C; Benzing T; Blandino G; Fanciulli M
Cell Death Dis; 2015 May; 6(5):e1764. PubMed ID: 25996291
[TBL] [Abstract][Full Text] [Related]
15. ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway.
Zhang G; Guan Y; Zhao Y; van der Straaten T; Xiao S; Xue P; Zhu G; Liu Q; Cai Y; Jin C; Yang J; Wu S; Lu X
Chem Biol Interact; 2017 Feb; 263():55-65. PubMed ID: 28027876
[TBL] [Abstract][Full Text] [Related]
16. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
Zheng H; Shao F; Martin S; Xu X; Deng CX
Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition.
Arima Y; Hirota T; Bronner C; Mousli M; Fujiwara T; Niwa S; Ishikawa H; Saya H
Genes Cells; 2004 Feb; 9(2):131-42. PubMed ID: 15009091
[TBL] [Abstract][Full Text] [Related]
18. Rad54B serves as a scaffold in the DNA damage response that limits checkpoint strength.
Yasuhara T; Suzuki T; Katsura M; Miyagawa K
Nat Commun; 2014 Nov; 5():5426. PubMed ID: 25384516
[TBL] [Abstract][Full Text] [Related]
19. Cyclin F suppresses B-Myb activity to promote cell cycle checkpoint control.
Klein DK; Hoffmann S; Ahlskog JK; O'Hanlon K; Quaas M; Larsen BD; Rolland B; Rösner HI; Walter D; Kousholt AN; Menzel T; Lees M; Johansen JV; Rappsilber J; Engeland K; Sørensen CS
Nat Commun; 2015 Jan; 6():5800. PubMed ID: 25557911
[TBL] [Abstract][Full Text] [Related]
20. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
